Filing search / 1993+ / Windtree Therapeutics, Inc. / Page 41

8-K

s7gy lucw

25 Aug 10

Departure of Directors or Certain Officers

12:00am

8-K

qkjc8w tq71i1y

4 Aug 10

Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results

12:00am

8-K

3n3sy leai1i

9 Jul 10

Departure of Directors or Certain Officers

12:00am

424B5

acbvu yzhta

18 Jun 10

Prospectus supplement for primary offering

12:00am

8-K

cdbczk9qt5h6c5

17 Jun 10

Discovery Labs Prices $10.0 Million Public Offering of

12:00am

424B5

dnbqzlqwsvx9h7

16 Jun 10

Prospectus supplement for primary offering

12:00am

424B3

9ap3pqwg29u

15 Jun 10

Prospectus supplement

12:00am

8-K

sxvt8enbyon9l

14 Jun 10

Discovery Labs Secures $35 Million Committed Equity Financing Facility

12:00am

8-K

cvxd5w

9 Jun 10

Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure

12:00am

8-K

nrzl jisdll5dk

9 Jun 10

Discovery Labs Receives FDA Guidance Regarding Preclinical Program to

12:00am

8-K

yxbjblku9 trv4

4 Jun 10

Discovery Labs Announces Listing Transfer to NASDAQ Capital Market

12:00am

8-K

1mai6jz5

21 May 10

Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

12:00am

8-K

mld5j

29 Apr 10

Other Events

12:00am

8-K

j3vfhfqh69txjo num

28 Apr 10

Entry into a Material Definitive Agreement

12:00am

8-K

uzbdkrlbgtdl2ms6 jn

28 Apr 10

Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

12:00am

424B5

h4jp8zcu

28 Apr 10

Prospectus supplement for primary offering

12:00am

S-8

g8z32qrno 4c

31 Mar 10

Registration of securities for employees

12:00am